Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen terminates alliance with Guilford

Executive Summary

Amgen acquired worldwide development and marketing rights to Guilford's FKBP neuroimmunophilin ligands, in development for nerve regeneration and repair, for all human therapeutic and diagnostic applications.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Equity
    • Intra-Biotech Deal

Related Companies

Advertisement
UsernamePublicRestriction

Register